Investigating the Interactive Effects of Berberine and Sitagliptin on Lipid Profile, Glucose and Insulin Levels in Diabetic Male Rats with Fatty Liver

Hepatic insulin resistance is associated with NAFLD and it is a major factor in the pathogenesis of type 2 diabetes and metabolic syndrome. Insulin resistance causes lipolysis in adipose tissue and disturbance in the regulation of lipid metabolism causes fat accumulation in the liver. In this study, the biological activities of Berberine and Sitagliptin to improve insulin resistance and lipid profile in Sprague-Dawley rats with type 2 diabetes was investigated. groups include 1: control (physiological serum as an alloxan solvent); 2: model (fatty liver + Alloxan); 3: Sitagliptin (fatty liver + Alloxan and Sitagliptin 10 mg/kg); 4: Berberine (fatty liver + Alloxan and Berberine 150mg/kg); 5: Berberine/Sitagliptin (fatty liver + Alloxan and Sitagliptin 5 mg/kg and Berberine 75 mg/kg). At the end of the treatment period, under anesthesia, Blood sampling done from the heart and lipid profile, glucose and insulin measured. The amount of triglyceride (p < 0.01), cholesterol (p < 0.05), LDL (p < 0.01), FFA (p < 0.05), fasting glucose (p < 0.05) and insulin (p < 0.01) in the coadministration group decreased compared to the model group and HDL increased, which was not significant. Berberine and Sitagliptin, especially when administered together, have a favorable effect on lipid metabolism and insulin resistance and can be considered as an effective treatment regimen for hyperlipidemia and fatty liver.